- Home
- CCEL vs BTAI Comparison
CCEL vs BTAI Comparison
Compare CCEL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEL | BTAI |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | 76 | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 35.8M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CCEL | BTAI |
|---|---|---|
| Price | $3.35 | $1.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 3.2K | ★ 650.7K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $25,384,279.00 | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | $384.00 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $1.01 |
| 52 Week High | $5.43 | $8.08 |
Technical Indicators
Market Signals| Indicator | CCEL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 56.83 |
| Support Level | $3.02 | $1.05 |
| Resistance Level | $3.92 | $1.39 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 21.51 | 70.97 |
Price Performance
Historical ComparisonAbout CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.